14 December 2020
The authorisation became vaccinations
Intensive-care nurse Sandra Lindsay received a Pfizer-BioNTech dose at Long Island Jewish Medical Center in Queens, among the first Americans vaccinated outside clinical trials. The first emergency authorisation had allowed the vaccine to be distributed three days earlier, for people aged 16 and over. That was the beginning of a rollout, rather than an assurance that everyone could immediately get a dose. The early programme prioritised health workers and people in long-term care. Turning the regulatory decision into protection required deliveries, appointments and a second dose under the original regimen.
First emergency authorisation · FDA · 11 December 2020 · Early vaccination · New York State · 14 December 2020
23 August 2021
Emergency use gave way to full approval
The FDA licensed the Pfizer-BioNTech vaccine as Comirnaty for people aged 16 and over. It was the first COVID-19 vaccine to receive full US approval, a different regulatory step from the December emergency authorisation. The agency reviewed longer follow-up from the clinical trial and manufacturing information. Some younger-age uses still remained under emergency authorisation at that point. Approval also came with warnings about myocarditis and pericarditis, inflammation affecting the heart or its surrounding tissue, and requirements for further safety studies. Full approval did not mean the vaccine had no risks, or that protection could never change.
10 September 2021 · study released
Delta exposed the difference between infection and severe illness
Real-world surveillance in 13 US jurisdictions showed that protection against infection weakened as Delta became predominant. The difference between vaccinated and not fully vaccinated adults remained much larger for hospital admissions and deaths. This was observational evidence covering several vaccines, not a Pfizer-only clinical trial. The result changed how the original promise should be understood: vaccination could substantially reduce the likelihood of a grave outcome without preventing every infection. The estimates described that period and those populations; they were not permanent guarantees.
18 March 2022 · study released
Hospital research found strong protection against the worst outcomes
A study across 21 US medical centres examined adults admitted between March 2021 and January 2022. Two or three doses of the Pfizer or Moderna mRNA vaccines were associated with 90% effectiveness against invasive ventilation or in-hospital death compared with no vaccination. The study combined those products and doses; the figure does not describe Pfizer alone. It also measured those severe endpoints, rather than protection against catching the virus. The observational design left room for confounding, and longer-term durability remained a separate question. Nevertheless, the hospital evidence provided a substantive answer beyond the original trial: vaccination was associated with a much lower risk of the outcomes families most feared.
27 February 2025 · study released
A later dose added protection, but the comparison had changed
Research on the 2024–2025 vaccines found additional protection against hospitalisation among adults aged 65 and over. Two surveillance networks estimated effectiveness at 45% and 46% in immunocompetent older adults during the first 7–119 days after vaccination. The comparison was with people who had not received that season’s dose, including people with earlier vaccinations or infections. These results cannot simply be set beside the 2022 figure as a measure of decline: the populations, doses, comparison groups and outcomes differed. They showed why the vaccination programme had become an updated-dose programme rather than a one-off intervention with a fixed lifetime effect.
25 June 2025
The heart-inflammation warning was updated
The FDA required revised warnings for Comirnaty and Spikevax about myocarditis and pericarditis after vaccination. The updated information included research on the 2023–2024 formulations and follow-up of people who developed myocarditis. Some cardiac MRI abnormalities persisted about five months later; the agency said their clinical significance was unknown. This was an update to a recognised safety concern, not a withdrawal of every mRNA vaccine. The vaccines remained approved, with the revised warning adding information about a risk already recognised when Comirnaty received full approval.
27 August 2025
The original emergency authorisation ended; the licensed product remained
The FDA revoked the Pfizer-BioNTech COVID-19 vaccine’s emergency use authorisation. Comirnaty continued as an approved product, so revocation did not amount to a ban on Pfizer’s licensed vaccine. The approved population narrowed: the FDA lists people aged 65 and over, and those aged 5–64 with at least one underlying condition putting them at high risk of severe COVID-19. Regulatory approval, vaccination recommendations and what a pharmacy can supply are distinct questions. The original broad emergency-use decision no longer described the later product’s approved use.
Emergency authorisation revoked · FDA · 27 August 2025 · Approved Comirnaty indications · FDA
27 August 2026
Another formula was approved, with further evidence still due
The FDA approved Comirnaty’s 2026–2027 formula and revised labelling. Pfizer and BioNTech said the updated vaccine targets the XFG variant. The approval letter also set out further safety and immune-response study commitments, with results and reports due in 2027. Those deadlines were future requirements, not completed findings. The first authorisation had led to vaccinations, full approval and evidence of protection against severe illness. But protection, safety information and access had not settled into one unchanging outcome: the vaccine itself and its approved population continued to change.
Approved Comirnaty indications · FDA · 2026–2027 formula approval and study commitments · FDA · 27 August 2026 · XFG formula approval announcement · Pfizer and BioNTech · 27 August 2026
The evidence
Sources for this update
- 01First emergency authorisation · FDA · 11 December 2020
- 02Early vaccination · New York State · 14 December 2020
- 03Full approval · FDA · 23 August 2021
- 04Delta-period outcomes · CDC · 10 September 2021
- 05Ventilation and death study · CDC · 18 March 2022
- 06Updated-dose effectiveness · CDC · 27 February 2025
- 07Revised myocarditis warning · FDA · 25 June 2025
- 08Emergency authorisation revoked · FDA · 27 August 2025
- 09Approved Comirnaty indications · FDA
- 102026–2027 formula approval and study commitments · FDA · 27 August 2026
- 11XFG formula approval announcement · Pfizer and BioNTech · 27 August 2026
Where the story stands
Protection and access remain open questions
The original authorisation achieved a rollout, a licensed vaccine and measured protection against severe illness. The question of lasting protection and access remains open: formulations and approved use have changed, and further studies are due. Historical study estimates describe their own periods and populations; they do not establish an individual’s present eligibility or benefit.